Development and Initial Testing of a Modified UroVysion-Based Fluorescence In Situ Hybridization Score for Prediction of Progression in Bladder Cancer.

Our aim was to predict progression of non-muscle-invasive bladder urothelial carcinomas (NMIUCs) into muscle-invasive disease by assessing cytogenetic abnormality of tumors with a new UroVysion scoring system.

Seventy-five bladder cancer cases (including 57 NMIUCs) were classified according to the quantitatively assessed degree of UroVysion-detected chromosomal abnormalities into urine fluorescence in situ hybridization score (UFS) groups: UFS I, II, and III. Cox time-to-event, Kaplan-Meier, and C-statistics analyses were performed.

UFS proved to be an independent prognostic factor of progression-free survival (PFS) and time to progression (TTP). NMIUCs with UFS III had a 34.05-fold increased hazard for progression to muscle-invasive cancer (TTP; 95% confidence interval, 5.841-198.5; P < .001) in comparison with UFS I to II cases. The addition of UFS to conventional risk scores increased the C-index for PFS and TTP.

UFS can indicate an increased risk for progression into muscle-invasive disease in patients with NMIUC and improves prognostic accuracy of the current clinical risk assessment systems.

American journal of clinical pathology. 2019 Nov 16 [Epub ahead of print]

Ildikó Kocsmár, Gábor Pajor, Benedek Gyöngyösi, Eszter Székely, Márton Varga, Éva Kocsmár, István Kenessey, Tamás Beöthe, Norbert Süle, Attila Majoros, Attila Szendrői, Péter Nyírády, András Kiss, Péter Riesz, Lotz Gábor

2nd Department of Pathology and , Budapest, Hungary., Department of Urology, Semmelweis University, Budapest, Hungary., Department of Pathology and , Pécs, Hungary., Department of Urology, Faculty of Medicine, University of Pécs, Pécs, Hungary., Department of Urology, Peterfy Sandor Municipal Hospital and Trauma Center, Budapest, Hungary., Department of Pathology & Laboratory Medicine, Roswell Park Cancer Institute, Buffalo, NY.